Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.
about
A Comprehensive Review of the Treatment of Atopic EczemaProfile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseasesBiological Treatments in Atopic DermatitisNew era of biologic therapeutics in atopic dermatitisSystemic therapy for atopic dermatitisPersonalized Medicine in AllergyMepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potentialSkin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in miceSpotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapyAnti-IL5 decreases the number of eosinophils but not the severity of dermatitis in Sharpin-deficient miceChanging roles of eosinophils in health and disease.Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach.Novel targeted therapies for eosinophil-associated diseases and allergyIgE-activated basophils regulate eosinophil tissue entry by modulating endothelial functionMepolizumab in eosinophilic disordersBiologic therapies targeting eosinophils: current status and future prospects.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Systemic Treatment.Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation.Anti-interleukin-5 antibody therapy in eosinophilic diseases.Mepolizumab.Management of itch in atopic dermatitis.A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.Glycoproteomic analysis of plasma from patients with atopic dermatitis: CD5L and ApoE as potential biomarkers.Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases.Severe vitamin E deficiency modulates airway allergic inflammatory responses in the murine asthma modelTherapeutic targets for new therapy for corticosteroid refractory asthma.Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract.What's new in atopic eczema?Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5.Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.Update on the management of chronic eczema: new approaches and emerging treatment optionsImmune modulation for treatment of allergic disease.Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.Clinical overview of cutaneous features in hypereosinophilic syndrome.Therapy of severe atopic dermatitis in adults.Guidelines for treatment of atopic eczema (atopic dermatitis) Part II.Long term treatment concepts and proactive therapy for atopic eczema.Immunology of atopic eczema: overcoming the Th1/Th2 paradigm.Advances in the diagnosis and therapeutic management of atopic dermatitis.
P2860
Q26765975-B028D077-D095-4E89-B342-E4D1852E8780Q26778683-19BD4807-6FEC-44E2-BF2D-70EB714E6EF1Q26799579-F895FBB0-5624-4383-B9BD-BA26F12D8C7EQ27001941-9CAFC2EE-A92E-4D07-81A8-9E8A5B5B943CQ27005835-16E08899-6C00-42F5-B69D-EDFF81F82D52Q28073074-ABA419D9-1742-463F-ACA0-EE1032EE4E59Q28080207-2F05ABA4-8B52-4660-A60D-D1EA0956BE28Q30543593-A963F66B-E5D6-4DDC-B62C-5E7433DE7C54Q33713754-9C95DCA8-2E02-4651-B693-0F2237CEAA11Q33780705-BA5DA071-189A-4E4E-A23C-57DF3C5363EEQ33787311-5A39E98B-037A-43C7-A524-EAC582F5A499Q34441795-157CB70A-F47A-4C4E-AA7D-C951373C0B96Q34444620-A8C58C7C-3B89-470B-A09B-9A76B00C845EQ35289192-70D4E8DB-A746-410D-BB26-5271292FDE80Q35446671-C73574AE-065E-4AA6-A955-86C7DB46A45CQ35565533-C3E28D13-A590-463D-A626-2EE9E53B8A37Q36214254-E34CF0F2-6723-45D5-B137-906097670639Q36437966-E5D034F6-A052-4C34-A2C9-660ECF4F4068Q36438486-15AC476C-B76C-4E2A-BB96-8E36A0B2DE02Q36977252-555A56F9-060A-46F4-8E88-00F224B1CA1DQ36991444-C717DA73-7076-44C0-83C7-4E6E3B328AD0Q37031192-F2A0AD46-DABF-4830-826F-CCC48AC376BFQ37059851-667DEEAD-BAC5-4D55-AF19-2063D82A120AQ37185022-4E57F44B-3803-4D8F-AE07-9E288204B929Q37336072-821B5C44-9B3E-42C1-AECB-A0081EB29D14Q37404698-55A02562-5C18-4EEF-922E-1BE1370EA888Q37573811-F1E52E65-27C4-408D-A4D4-EFF73E831D3AQ37731037-C9D7D6EB-0AA4-44E5-A5C1-6AA7162B7D06Q37740142-CD615462-E695-4682-ABAC-1D460673282FQ37755233-860F9739-1D5C-403A-A00B-435F3679DF07Q37846670-3E1A6A54-E338-4918-B792-89FFE3FD7ED3Q37857682-1C75A104-6115-4721-A4AE-F64E55E2A495Q37891140-39DBDF98-C2D8-45FA-9B18-121B072ED28CQ37957225-2EBBFC1F-B51B-4B71-8FA2-2EAC3208BBC2Q37987470-C7B88A5C-C65F-4661-AB55-9A334742E264Q38011193-2CFFFB48-319C-45D9-A4BE-731474C2C3EBQ38027604-DB2EAF94-9866-45DC-9A9E-7831577C977DQ38033549-8E1727A5-D3BC-4077-BED2-73C6E5CCCADDQ38124385-1C58E1D5-D5A5-454C-BF81-2404207D45E5Q38211352-BF908ADC-CC4C-4222-8996-99455EFFD427
P2860
Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Anti-IL-5 recombinant humanize ...... reatment of atopic dermatitis.
@en
Anti-IL-5 recombinant humanized monoclonal antibody
@nl
type
label
Anti-IL-5 recombinant humanize ...... reatment of atopic dermatitis.
@en
Anti-IL-5 recombinant humanized monoclonal antibody
@nl
prefLabel
Anti-IL-5 recombinant humanize ...... reatment of atopic dermatitis.
@en
Anti-IL-5 recombinant humanized monoclonal antibody
@nl
P2093
P2860
P1433
P1476
Anti-IL-5 recombinant humanize ...... treatment of atopic dermatitis
@en
P2093
Bruijnzeel-Koomen CA
Laifaoui J
Oldhoff JM
P2860
P304
P356
10.1111/J.1398-9995.2005.00791.X
P577
2005-05-01T00:00:00Z